posted
avVaa World Health Care Products Signs First U.S. Distributor Monday May 22, 8:00 am ET - To Distribute avVaa's Newest Line of Equine Products -
LUMBY, British Columbia, May 22 /PRNewswire-FirstCall/ -- avVaa World Health Care Products Inc. (OTC Bulletin Board: AVVW - News), a global biotechnology company offering therapeutic, natural skin and health care products, announced today that it has signed a distribution agreement with American distributor Horse Mountain Distributing, LLC, based in Shelbyville, Tennessee.
According to terms of the agreement, Horse Mountain Distributing (HMD) will distribute avVaa's avVaa Care Professional product line, a unique line of therapeutic, all natural products designed for the specific needs of horses and their quality-conscious handlers, to its established network of dealers throughout the United States.
posted
AVVAA WORLD HEALTH CARE PROD (U-AVVW) - News Release avVaa World Health Care Products Introduces Private Label Program
2006-05-25 10:00 ET - News Release
LUMBY, British Columbia, May 25 /PRNewswire-FirstCall/ -- avVaa World Health Care Products, Inc. , a biotech company offering global customers therapeutic skin and health care products, announced today the launch of the Company's private label program for its human and pet skincare lines.
For its primary line of quality human skin care products, avVaa is actively seeking collaboration with drug store chains and manufacturers to provide private labeling for its NeuroSkin(TM) mild skin moisturizer, NeuroSkin spray for eczema/psoriasis relief and its NeuroSkin acne treatment. avVaa's NeuroSkin line includes high quality products that aid in the treatment of a wide variety of conditions, including: eczema, psoriasis, dermatitis, acne and rosacea. avVaa is also actively negotiating private label partnerships for its acne, burn applications and various cosmetic lines.
"Now that our high quality, therapeutic products will be actively distributed in U.S. and Canada, private labeling allows our products to benefit from immediate brand recognition and gain rapid market acceptance while providing avVaa immediate access to revenue building opportunities," said Jack Farley, CEO and chairman of avVaa World Health Care Products. "We look forward to growing our business and product lines while partnering with some of the best names in retail throughout Canada and the U.S."
avVaa is currently negotiating with a pet care product manufacturer for a private label agreement for its pet and equine dermalustre(TM) products- therapeutic, all natural skin and coat treatment for animals. avVaa is also actively seeking partnerships with retail pet care chain stores to develop private label products that benefit from avVaa's proven formulas as well as the established brand recognition and loyalty of the U.S. and Canada's most popular retailers.
For more information on private labeling opportunities with avVaa, please contact George Roadman, 508-282-1454.
About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers.
avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC NeuroSkin(TM) line of skin care products through mass, food and drug channels in the United States and globally. The Company's secondary line of equine and pet care related products are already being distributed throughout all of Canada and parts of the United States. For more information, visit: http://www.avvaa.com or http://www.otcfn.com/avvw.
Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of avVaa World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
Contact: Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349
or
Rick McCaffrey at OTC Financial Network, Investor Relations, 781-444-6100 x625.
Tracy Bagatelle-Black Mark Wachs & Associates 661/263-1842 tbagatelleblack*earthlink.net avVaa World Health Care Products, Inc.
CONTACT: Merle Goertz - West Coast - of avVaa World Health Care Products, +1-604-688-2349; or Rick McCaffrey, Investor Relations at OTC Financial Network, +1-781-444-6100 x625; or Tracy Bagatelle-Black of Mark Wachs & Associates, +1-661-263-1842, tbagatelleblack*earthlink.net
posted
i've heard rumors that they are signing on walgreens, but even if it's cvs or another chain, the big chain appears to be liking and expanding the testing reach, so that's very good. (april pr)
Thinking out loud: would the company just announce a huge deal 'semi' out of the blue, or build up some audience beforehand with a few initial PR's that in and of themselves are good and then put out a huge PR... imo, they were wise to start with a few PR's before the memorial day weekend, and now that everyone is well rested and coming back to the markets, time for a big PR.
posted
AVVW is OTCbargains.com stock pick - I did not hear the rumors - but this is what I read on - http://www.otcbargains.com/ -
Business: Biotechnology/Biomedical
OTC BB Symbol: AVVW Market Price $0.042 52-Week Range: $0.06 - 0.27 Average Daily Volume: 243,000 Common Shares Outstanding: 50.2 Million Estimated Public Float: 29.5 Million Market Cap: 2.6 Million
Explosive Market Potential - More than 40 million Americans are afflicted with a skin disease, and currently spend more than $4 billion per year on treatments. Additionally, secondary lines of pet and equine products for veterinary applications represent a growing $44 billion market.
Patented Technologies - AVVAA's registered FDA-compliant product line are popular European treatments that are proven effective, all natural, non-toxic and available over-the-counter with multiple applications,including healthcare, equine and pet usage.
Strategic Partnerships - AVVAA has contracts with leading pharmaceutical manufacturing, marketing and sales distribution companies in the U.S. and established strategic agreements in place throughout Canada. The Company is rapidly adding distribution partners to grow its worldwide footprint in the near term.
Dynamic Applications - Intensive R&D has led to seven new product lines, including a complete line of animal/pet skin care, dandruff shampoo, and nontoxic insect repellent and insect bite treatment that will be available in the near term.
Expansive Market
Skin problems are exceedingly common, resulting in American's spending close to $4 billion each year for the treatment of psoriasis, eczema and acne. AVVAA's product pipeline will target more than 40 million Americans who suffer from a dermatological condition. The statistics are staggering*: -85% of the U.S. population between the ages of 12-25 years develops some form of acne -A total of 17 million Americans are plagued with acne -Over 16 million people are affected by eczema -The psoriasis market is continuing to grow with the aging population, affecting from 0.5% to 3% of the world's population At present, there is no cure for psoriasis, eczema or acne. In fact, now that two of the best-selling popular treatments for eczema are under increasing FDA scrutiny for a possible link to cancer, patients who have been initially recommended by their doctors to use these products or others of the present toxic therapies may eventually be forced to stop that therapy, and seek out a lesser toxic treatment. Other products that are presently available to deal with these skin problems are in the prescription category and considerably more expensive than OTC products. A sizable proportion of other current products have constituent elements that could be considered harmful, especially with prolonged use. These include cortisone, antibiotics, hydrogen peroxide, alcohol and other toxic compounds.
In marked contrast, AVVAA's Neuroskin products offer an all natural, non-toxic, medically safe therapy to relieve the aggravation and pain of skin disease, with the convenience of over-the-counter (OTC) availability. In German clinical trials and research, the natural, non-toxic range of Neuroskin products was found to be 99.5% effective in relieving the symptoms of psoriasis, eczema and dermatitis with no adverse reactions or toxicity in adverse reaction and safety studies. These advantages create a dynamic opportunity for AVVAA to rapidly gain market acceptance of its products in the U.S. and abroad.
Aggressive Growth Strategies AVVAA's sales and marketing division initiates both traditional and Internet marketing to drive sales in its target markets.
Building a National Presence: Fueled by rapid market interest in Canada, AVVAA plans for an extensive U.S. and global roll-out. Now that sufficient manufacturing facility has been secured, the Company is negotiating with national marketing agencies that specialize in bringing new companies with unique products to the marketplace.
As Neuroskin becomes registered FDA-compliant as over-the-counter pharmaceutical and cosmetic skin care, sales efforts will be targeted toward forming lucrative private label agreements with leading, worldwide cosmetic companies. Additionally, the Company is securing a number of strategic distribution agreements with established U.S. and Canadian distributors to reach targeted markets throughout North America.
Global Marketing Online: According to Forrester Research, the over-the-counter drugs and health and beauty aids sectors will contribute $1.9 billion and $900 million, respectively, to the online retail category.
To capitalize on this high-growth market, AVVAA has developed a comprehensive information and e-commerce business-to-consumer site (http://www.help4skincare.com/) and a business-to- business site (http://www.avvaa.com/). The Company's B2B site provides for a seamless supply chain management system, which will create and effectively manage global partners for its products.
Innovative Applications: AVVAA is introducing other key products based on its intensive R&D efforts and market research studies. These include non-toxic insect repellent, a comprehensive line of hair care products for the effective treatment for psoriasis, eczema, dermatitis and dandruff, as well as additional bath and spa products.
IP: Logged |
I'd read the rumors on RB (lol, i know), but also a few other locations. In their previous PR they indicated 'someone' was testing their products and was happy and expanding the testing area.
"One important strategic relationship with a successful marketing company headquartered in the United States, has created a host of targeted sales opportunities for avVaa, including a beta test that is ongoing now in a large U.S. city at a number of locations for a major drug store chain. The feedback on the beta testing to date from the national retailer points only to sales successes and additional store rollouts based upon positive response."
and
"For the past six months, initiatives have been underway to introduce a full line of avVaa cosmetic skin care products in a revolutionary way -- in both big box, high volume retailers as well as traditional upscale retailers. In fact, we expect to have avVaa cosmetic products in at least one very well known chain by the end of this year."
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
